ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference

By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provi...

Descripción completa

Detalles Bibliográficos
Autores principales: De Bacco, Francesca, Boccaccio, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632286/
https://www.ncbi.nlm.nih.gov/pubmed/34859149
http://dx.doi.org/10.1080/23723556.2021.1990677
_version_ 1784607729108647936
author De Bacco, Francesca
Boccaccio, Carla
author_facet De Bacco, Francesca
Boccaccio, Carla
author_sort De Bacco, Francesca
collection PubMed
description By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provide insights on why some glioblastomas may rely on ERBB3 and how to recognize them.
format Online
Article
Text
id pubmed-8632286
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-86322862021-12-01 ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference De Bacco, Francesca Boccaccio, Carla Mol Cell Oncol Commentary By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provide insights on why some glioblastomas may rely on ERBB3 and how to recognize them. Taylor & Francis 2021-10-27 /pmc/articles/PMC8632286/ /pubmed/34859149 http://dx.doi.org/10.1080/23723556.2021.1990677 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Commentary
De Bacco, Francesca
Boccaccio, Carla
ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference
title ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference
title_full ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference
title_fullStr ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference
title_full_unstemmed ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference
title_short ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference
title_sort erbb3 as a therapeutic target in glioblastoma: overexpression can make the difference
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632286/
https://www.ncbi.nlm.nih.gov/pubmed/34859149
http://dx.doi.org/10.1080/23723556.2021.1990677
work_keys_str_mv AT debaccofrancesca erbb3asatherapeutictargetinglioblastomaoverexpressioncanmakethedifference
AT boccacciocarla erbb3asatherapeutictargetinglioblastomaoverexpressioncanmakethedifference

Ejemplares similares